Clinical trial
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
NCT00005598 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005598 |
|---|---|
| Title | Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome |
| Official title | A Phase II Trial of 5-Azacytidine (NSC #102816) and Ethyol (Amifostine) in the Treatment of Adults With Myelodysplastic Syndromes |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, azacitidine |
| Start date | Oct 1, 2000 |
| Primary completion | Dec 1, 2001 |
| Completion | Mar 1, 2002 |
| First posted | Dec 16, 2003 |
| Last update posted | Dec 21, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: